News
Phase II Trial Shows Promise for Pre-Surgical PRRT in Pancreatic Neuroendocrine Tumors
Using PRRT with 177Lu-DOTATATE before surgery is both safe and effective for patients with non-functioning pancreatic neuroendocrine tumors and certain risk factors, according to the
Think NENs to Educate Primary Care Physicians
The Think NENs Global Educational Program for Primary Care Physicians has been launched by the International Neuroendocrine Cancer Alliance (INCA). The Think NENs Global Educational
Dr. Santoro Fernandes Receives 2024 NANETS/NETRF BTSI Grant
The Neuroendocrine Tumor Research Foundation (NETRF), in partnership with the North American Neuroendocrine Tumor Society (NANETS), is proud to announce Victor Santoro Fernandes, PhD, as
Phase II Trial Shows Potential for Second-Line Therapies for Neuroendocrine Carcinomas
Neuroendocrine carcinomas (NECs) are uncommon and aggressive cancers with limited treatment options after the failure of platinum-based therapies. A recently concluded phase II trial investigated
Historic CAR T trial opens at University of Pennsylvania
The University of Pennsylvania is now enrolling patients in the new phase 1/2 multi-center clinical trial for CAR T cell therapy. The trial includes patients
NETRF Scientific Advisor Dr. Daniel Halperin Takes on Pivotal Role at Winship Cancer Institute of Emory University
NETRF is pleased to announce that Daniel Halperin, MD, one of our distinguished Board of Scientific Advisors members, has been appointed Vice Chair of Clinical
Taking a Look at Proteins: Pioneering NETRF-Funded Research in Pancreatic Neuroendocrine Tumors
NETRF congratulates Dr. Michael Roehrl on his research progress and recent publication. NETRF’s recent Investigator Award to Michael Roehrl, MD, PhD, MBA, Chief of Pathology at…
Another CAR T-Cell Clinical Trial Open to Neuroendocrine Cancer Patients
A phase I CAR T-cell clinical trial targeting the molecule IL13Rα2 found on the surface of some tumors is being conducted at the University of
Honoring Leadership: Drs. Shivdasani, Fisher, and Chung Named BOSA Emeritus Members
The Neuroendocrine Tumor Research Foundation (NETRF) extends its deepest gratitude to Ramesh Shivdasani, MD, PhD (Dana-Farber Cancer Institute), George Fisher, MD, PhD (Stanford University), and Daniel Chung, MD (Massachusetts General Hospital) for their exceptional service as members and former Chairs of the NETRF Board of Scientific Advisors (BOSA).
Promising Advancement in Neuroendocrine Tumor Treatment: FDA Accepts Cabozantinib Application
The Neuroendocrine Tumor Research Foundation is excited to share an important update in the field of neuroendocrine tumor (NET) treatment. On August 6, 2024, Exelixis